Akorn (AKRX) 8-K Akorn, Inc. Announces FDA Approval for Hydromorphone Hydrochloride Injection 10mg/ml in 1ml, 5ml and 50ml Doses

UNITED STATESSECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549

FORM 8-K

CURRENT REPORTPursuant to Section 13 or 15 (d) of theSecurities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 15, 2010
Akorn, Inc.
(Exact Name of Registrant as Specified in Charter)

Louisiana	001-32360	72-0717400
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

1925 West Field Court, Suite 300 Lake Forest, IL	60045
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s telephone number, including area code:

(847) 279-6100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01  Other Events.

On April 15, 2010, the Company issued a press release announcing that the U.S. Food and Drug Administration (FDA) has granted approval of the Company’s Abbreviated New Drug Application (ANDA) for the generic version of Dilaudid-HP® (Hyromorphone Hydrochloride) 10mg/ml Injection.  The Company further announced that it had commenced the manufacture of Vancomycin HCL for Injection 5gm/vial at its plant in Decatur, Illinois on a contract basis for sale through its joint venture subsidiary, Akorn-Strides LLC.

Item 9.01  Financial Statements and Exhibits.

(d) Exhibits.
99.1	Press release issued by Akorn, Inc., dated April 15, 2010, announcing FDA approval of the Company’s ANDA for the generic version of Dilaudid-HP® (Hyromorphone Hydrochloride) 10mg/ml Injection.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		AKORN, INC.
Date:	April 15, 2010	By:	/s/ Timothy A. Dick
			Timothy A. Dick
			Sr. Vice President, Chief Financial Officer